OLMA Stock Risk & Deep Value Analysis
Olema Pharmaceuticals Inc
Healthcare • Biotechnology
DVR Score
out of 10
The Bottom Line on OLMA
We analyzed Olema Pharmaceuticals Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran OLMA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
OLMA Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
About Olema Pharmaceuticals Inc (OLMA)
Sector
Healthcare
Industry
Biotechnology
Market Cap Category
mid
Market Cap
$2.00B
OLMA Deep Value Analysis
Compare OLMA to Similar Stocks
See how Olema Pharmaceuticals Inc stacks up against related companies in our head-to-head analysis.
OLMA Red Flags & Warning Signs
- âš
Negative or inconclusive Phase 3 clinical trial results for Palazestrant
- âš
Delayed regulatory review or outright rejection by FDA/EMA
- âš
Launch of a superior competitor oral SERD or alternative therapy
- âš
Significant cash burn leading to dilutive financing rounds
Unlock OLMA Red Flags & Risk Warnings
Create a free account to see the full analysis
OLMA Financial Health Metrics
Market Cap
$2.00B
OLMA Competitive Moat Analysis
Sign in to unlockMoat Rating
Narrow
Moat Trend
Expanding
Moat Sources
1 Identified
The moat is currently narrow, highly dependent on the robust clinical profile and patent protection of Palazestrant. If Phase 3 data confirms a best-in-class profile, the moat will strengthen significantly due to efficacy and safety differentiation, making it hard for follow-on SERDs to compete.
OLMA Competitive Moat Analysis
Sign up to see competitive advantages
OLMA Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Expected Phase 3 EMERALD-1 (Palazestrant + abemaciclib) data readout for ER+/HER2- advanced breast cancer (Q1-Q2 2026)
- •Anticipated Phase 3 OPAL data readout (Palazestrant monotherapy) for ER+/HER2- mBC (Mid-2026)
- •Potential pre-NDA meeting with FDA (H2 2026)
Medium-Term (6-18 months)
- •Submission of New Drug Application (NDA) to FDA for Palazestrant (late 2026 / early 2027)
- •Marketing Authorization Application (MAA) submission to EMA (2027)
- •Strategic partnerships for ex-US commercialization
Long-Term (18+ months)
- •Achievement of best-in-class oral SERD status for Palazestrant, driving significant market share capture
- •Expansion of Palazestrant into earlier lines of therapy or other hormone-sensitive cancers
- •Potential for acquisition by a major pharmaceutical company seeking to bolster oncology pipeline
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
OLMA Bull Case: What Could Go Right
- ✓
Positive Phase 3 EMERALD-1 and OPAL data readouts for Palazestrant
- ✓
Timely and successful submission of NDA/MAA applications
- ✓
Any signs of a potential acquisition by a larger pharmaceutical entity
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.
